Free Trial

Eupraxia Pharmaceuticals Q4 2023 Earnings Report

Eupraxia Pharmaceuticals logo
$3.10 -0.17 (-5.20%)
As of 04/3/2025 03:48 PM Eastern

Eupraxia Pharmaceuticals EPS Results

Actual EPS
-$0.17
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Eupraxia Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eupraxia Pharmaceuticals Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Remove Ads

Eupraxia Pharmaceuticals Earnings Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Eupraxia Pharmaceuticals reports FY24 EPS (76c), consensus (63c)
See More Eupraxia Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eupraxia Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eupraxia Pharmaceuticals and other key companies, straight to your email.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals (NASDAQ:EPRX) is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

View Eupraxia Pharmaceuticals Profile

More Earnings Resources from MarketBeat